Probiogen Signs Therapeutic Protein Process Development Contract With Virdante Pharmaceuticals
|| Print ||
|Wednesday, 28 April 2010 10:00 (UTC + 2)|
Berlin, Germany, April 28th, 2010 / b3c newswire /- ProBioGen AG (“ProBioGen”), a technology and service provider for the development and production of biopharmaceutical drug substances today announced signing a contract with Virdante Biopharmaceuticals, Inc., a US-based biopharmaceutical development company (“Virdante”).
ProBioGen will contribute producer cell line development and process engineering for one of Virdante’s proprietary therapeutic proteins. Virdante’s protein products are unique in that they incorporate the company’s proprietary “Sialic Switch” technology that improves the anti-inflammatory properties of an antibody for autoimmune and inflammatory diseases. Virdante selected ProBioGen for its expertise in developing royalty-free pharmaceutical cell lines and robust, economical processes for GMP-manufacturing.
“We are highly impressed by Virdante´s products and strategies and their compelling scientific rationale to improve human proteins. We are excited to contribute our knowledge in harnessing the cellular machinery to maximize productivity for this ambitious project“, commented Dr. Volker Sandig, Chief Scientific Officer of ProBioGen.
About Virdante - www.virdante.com
Contact for ProBioGen:
Dr Gertraud Unterrainer, CFO